Sabin PDP Begins Phase 1 Clinical Trial to Co-Administer Two Novel Hookworm Vaccine Candidates in Brazil

WASHINGTON, D.C. — April 28, 2016 — The Sabin Vaccine Institute (Sabin) today announced that its Product Development Partnership (Sabin PDP) began a Phase 1 clinical trial of Na-APR-1 (M74)/Alhydrogel® co-administered with Na-GST-1/Alhydrogel in Brazilian adults.

It takes more than a vaccine to make a successful immunization program. This World Immunization Week, we are taking a look at some of the factors that contribute to effective immunization programs.

This article was originally posted on the DSW Blog.

Photo: Sabin CEO Michael W. Marine, Ambassador (Ret.), with Former President of Ghana, John Kufuor

Pages